Schroder Investment Management Group’s Summit Therapeutics SMMT Stock Holding History

Schroder Investment Management Group’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12M	Buy	835,963 +584,572	+233%	+$10.4M	0.01%	640
2026 Q1	$4.27M	Hold	251,391	–	–	﹤0.01%	809
2025 Q4	$4.4M	Buy	251,391 +8,772	+4%	+$165K	﹤0.01%	768
2025 Q3	$5.13M	Buy	242,619 +98,112	+68%	+$2.38M	﹤0.01%	770
2025 Q2	$3.08M	Sell	144,507 -89,090	-38%	-$2.03M	﹤0.01%	845
2025 Q1	$4.75M	Buy	+233,597	New	+$4.69M	﹤0.01%	763

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Schroder Investment Management Group's SMMT Position: Q2 2026 in Review

Schroder Investment Management Group increased its Summit Therapeutics (SMMT) stake by 233% in Q2 2026, buying an estimated $10.4M and bringing the position to 835,963 shares worth $12M. The position accounts for 0.01% of the portfolio, ranked #640.

Schroder Investment Management Group first reported a position in SMMT in Q1 2025 and has held it in 6 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Schroder Investment Management Group held 835,963 shares of Summit Therapeutics worth $12M as of Q2 2026.
Schroder Investment Management Group bought 584,572 Summit Therapeutics shares in Q2 2026, an estimated $10.4M.
Summit Therapeutics made up 0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #640 holding.
Schroder Investment Management Group first reported a position in Summit Therapeutics in Q1 2025 and has held it in 6 quarters since.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.